公开(公告)号：EP1200103B1

公开(公告)日：2008-08-13

申请号：EP00948171.4

申请日：2000-07-28

申请人： Protexeon Limited

发明人： FRANKS, Nicholas P. Biophysics Sec., BlackettLab. ,  MAZE, Mervyn Dept. Anaesthetics, Imperial College

IPC分类号： A61K33/00 ,  A61P25/28 ,  A61P25/36

CPC分类号： A61K33/00 ,  Y10S514/812 ,  Y10S514/816 ,  Y10S514/959

摘要： The present invention relates to the use of xenon as a neuroprotectant and/or as an inhibitor of synaptic plasticity. In a preferred aspect, the xenon acts as an NMDA antagonist. The present invention also provides a method of reducing the level of activation of the NMDA receptors in a mammal, the method comprising modulating the activity of the NMDA receptor by administering to the mammal a therapeutically effective amount of xenon, wherein said reduction achieves neuroprotection and/or an inhibition of synaptic plasticity. A further embodiment of the invention provides a pharmaceutical composition for providing neuroprotection and/or inhibition of synaptic plasticity, together with a process for the process for the preparation thereof.

摘要翻译： 本发明涉及氙作为神经保护剂和/或作为突触可塑性抑制剂的用途。 在优选的方面，氙充当NMDA拮抗剂。 本发明还提供了降低哺乳动物NMDA受体活化水平的方法，所述方法包括通过向哺乳动物施用治疗有效量的氙来调节NMDA受体的活性，其中所述减少实现神经保护和/ 或抑制突触可塑性。 本发明的另一个实施方案提供用于提供神经保护和/或抑制突触可塑性的药物组合物，以及其制备方法。